Stem definition | Drug id | CAS RN |
---|---|---|
calcium channel blockers, nifedipine derivatives | 1947 | 39562-70-4 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.92 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 16.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 6.10 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 25 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 8.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1985 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
General physical health deterioration | 80.24 | 37.14 | 58 | 2073 | 142376 | 50460617 |
Product prescribing error | 76.86 | 37.14 | 30 | 2101 | 20931 | 50582062 |
Fall | 75.76 | 37.14 | 81 | 2050 | 334851 | 50268142 |
Antinuclear antibody negative | 74.26 | 37.14 | 12 | 2119 | 204 | 50602789 |
Coombs positive haemolytic anaemia | 68.86 | 37.14 | 12 | 2119 | 327 | 50602666 |
Herpes simplex reactivation | 66.97 | 37.14 | 12 | 2119 | 385 | 50602608 |
Gastritis haemorrhagic | 52.43 | 37.14 | 12 | 2119 | 1325 | 50601668 |
Antiphospholipid syndrome | 50.93 | 37.14 | 12 | 2119 | 1505 | 50601488 |
Complex regional pain syndrome | 47.67 | 37.14 | 12 | 2119 | 1981 | 50601012 |
Hypertensive angiopathy | 45.67 | 37.14 | 7 | 2124 | 83 | 50602910 |
Lymphopenia | 45.64 | 37.14 | 19 | 2112 | 15602 | 50587391 |
Premature baby | 42.71 | 37.14 | 19 | 2112 | 18318 | 50584675 |
Hypertension | 40.48 | 37.14 | 47 | 2084 | 211156 | 50391837 |
Anxiety disorder | 40.40 | 37.14 | 12 | 2119 | 3661 | 50599332 |
Hyperlipidaemia | 40.34 | 37.14 | 18 | 2113 | 17472 | 50585521 |
Hypertensive crisis | 38.42 | 37.14 | 16 | 2115 | 13138 | 50589855 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Dizziness | 64.52 | 30.82 | 79 | 2394 | 189605 | 29382449 |
Product prescribing error | 64.50 | 30.82 | 31 | 2442 | 17945 | 29554109 |
Rectal prolapse | 57.08 | 30.82 | 11 | 2462 | 260 | 29571794 |
Intraductal papillary mucinous neoplasm | 54.59 | 30.82 | 11 | 2462 | 329 | 29571725 |
Vena cava injury | 53.11 | 30.82 | 10 | 2463 | 208 | 29571846 |
Renal cyst haemorrhage | 52.67 | 30.82 | 11 | 2462 | 394 | 29571660 |
SARS-CoV-2 antibody test positive | 52.45 | 30.82 | 10 | 2463 | 223 | 29571831 |
Syncope | 50.97 | 30.82 | 47 | 2426 | 81324 | 29490730 |
Spinal osteoarthritis | 39.06 | 30.82 | 16 | 2457 | 6340 | 29565714 |
Carotid arteriosclerosis | 38.82 | 30.82 | 11 | 2462 | 1427 | 29570627 |
Left ventricular hypertrophy | 38.23 | 30.82 | 16 | 2457 | 6687 | 29565367 |
Tongue biting | 35.98 | 30.82 | 9 | 2464 | 724 | 29571330 |
Delayed graft function | 35.64 | 30.82 | 11 | 2462 | 1916 | 29570138 |
Postrenal failure | 35.38 | 30.82 | 8 | 2465 | 417 | 29571637 |
Osteochondrosis | 35.12 | 30.82 | 9 | 2464 | 798 | 29571256 |
Abdominal wall haemorrhage | 33.56 | 30.82 | 7 | 2466 | 249 | 29571805 |
Mean cell volume increased | 32.87 | 30.82 | 11 | 2462 | 2478 | 29569576 |
General physical health deterioration | 31.85 | 30.82 | 41 | 2432 | 102816 | 29469238 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Product prescribing error | 142.76 | 32.48 | 61 | 4068 | 35208 | 64459395 |
General physical health deterioration | 111.25 | 32.48 | 97 | 4032 | 204328 | 64290275 |
Dizziness | 94.34 | 32.48 | 126 | 4003 | 430037 | 64064566 |
Syncope | 90.11 | 32.48 | 77 | 4052 | 157558 | 64337045 |
Tongue biting | 68.43 | 32.48 | 17 | 4112 | 1743 | 64492860 |
Fall | 59.45 | 32.48 | 100 | 4029 | 416726 | 64077877 |
Vena cava injury | 55.24 | 32.48 | 10 | 4119 | 220 | 64494383 |
SARS-CoV-2 antibody test positive | 54.44 | 32.48 | 10 | 4119 | 239 | 64494364 |
Renal cyst haemorrhage | 54.15 | 32.48 | 11 | 4118 | 451 | 64494152 |
Intraductal papillary mucinous neoplasm | 51.34 | 32.48 | 11 | 4118 | 586 | 64494017 |
Bradycardia | 50.30 | 32.48 | 49 | 4080 | 118170 | 64376433 |
Hypertensive angiopathy | 41.52 | 32.48 | 7 | 4122 | 100 | 64494503 |
Rectal prolapse | 39.73 | 32.48 | 11 | 4118 | 1715 | 64492888 |
Dysuria | 38.01 | 32.48 | 27 | 4102 | 42030 | 64452573 |
Carotid arteriosclerosis | 37.71 | 32.48 | 11 | 4118 | 2068 | 64492535 |
Benign prostatic hyperplasia | 37.51 | 32.48 | 16 | 4113 | 9149 | 64485454 |
Left ventricular hypertrophy | 36.95 | 32.48 | 16 | 4113 | 9490 | 64485113 |
Hypertensive crisis | 35.20 | 32.48 | 19 | 4110 | 18229 | 64476374 |
Postrenal failure | 35.11 | 32.48 | 8 | 4121 | 566 | 64494037 |
Delayed graft function | 33.60 | 32.48 | 11 | 4118 | 3025 | 64491578 |
None
Source | Code | Description |
---|---|---|
ATC | C08CA08 | CARDIOVASCULAR SYSTEM CALCIUM CHANNEL BLOCKERS SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS Dihydropyridine derivatives |
ATC | C09BB06 | CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and calcium channel blockers |
MeSH PA | D000959 | Antihypertensive Agents |
MeSH PA | D002121 | Calcium Channel Blockers |
MeSH PA | D000077264 | Calcium-Regulating Hormones and Agents |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D049990 | Membrane Transport Modulators |
MeSH PA | D014665 | Vasodilator Agents |
CHEBI has role | CHEBI:35620 | vasodilator agents |
CHEBI has role | CHEBI:35674 | antihypertensive drugs |
CHEBI has role | CHEBI:38215 | calcium channel blockers |
CHEBI has role | CHEBI:176497 | geroprotectors |
None
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.37 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Voltage-dependent L-type calcium channel subunit alpha-1D | Ion channel | GATING INHIBITOR | IC50 | 8.40 | IUPHAR | IUPHAR | |||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | BLOCKER | Ki | 9.60 | CHEMBL | SCIENTIFIC LITERATURE | |||
Intermediate conductance calcium-activated potassium channel protein 4 | Ion channel | BLOCKER | IC50 | 7.60 | IUPHAR | ||||
Voltage-dependent calcium channel gamma-1 subunit | Ion channel | WOMBAT-PK | |||||||
Transthyretin | Secreted | IC50 | 5.92 | WOMBAT-PK | |||||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.52 | DRUG MATRIX | |||||
Voltage-dependent T-type calcium channel subunit alpha-1H | Ion channel | IC50 | 5.06 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1F | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
Sodium channel alpha subunits; brain (Types I, II, III) | Ion channel | IC50 | 4.44 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 5.52 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.08 | WOMBAT-PK | |||||
Adenosine receptor A1 | GPCR | Ki | 5.05 | CHEMBL | |||||
Adenosine receptor A2a | GPCR | Ki | 4.64 | CHEMBL | |||||
Voltage-dependent L-type calcium channel subunit alpha-1C | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
Voltage-dependent L-type calcium channel subunit alpha-1S | Ion channel | GATING INHIBITOR | IC50 | 6 | IUPHAR | ||||
Platelet-activating factor receptor | GPCR | Ki | 4.13 | CHEMBL |
ID | Source |
---|---|
N0000167238 | NUI |
D00629 | KEGG_DRUG |
C0028127 | UMLSCUI |
CHEBI:7582 | CHEBI |
CHEMBL475534 | ChEMBL_ID |
CHEMBL251230 | ChEMBL_ID |
CHEMBL268609 | ChEMBL_ID |
DB01054 | DRUGBANK_ID |
D009568 | MESH_DESCRIPTOR_UI |
4507 | PUBCHEM_CID |
2334 | IUPHAR_LIGAND_ID |
4739 | INN_ID |
9B627AW319 | UNII |
7441 | RXNORM |
005383 | NDDF |
444757009 | SNOMEDCT_US |
None